p>44 patients have undergone scintimammography using both 99mTc.Sestamibi and 99mTc.Oxidronate; 23 subsequently having histologically confirmed cancer. Surgical specimens from these 23 patients confirmed axillary disease in 8, the remaining 15 being negative. Scintimammograms reported in the knowledge of conventional triple assessment were identical for both radiopharmaceuticals; giving 3 true positives (TP) and 5 false negatives (FN). The 21 patients without evidence of breast cancer were all true negative on both scintimammograms. A further 11 breast cancer patients underwent 99mTc.Sestamibi scintimammography alone. Of these only 3 had histologically confirmed axillary involvement; 1TP and 2FN from 99mTc.Sestamibi reports. Combining these results in breast cancer patients demonstrates no significant difference (5% level) between the two radiopharmaceuticals.
| . | n | Sensitivity | Specificity | Accuracy | PPV | NPV |
|---|---|---|---|---|---|---|
| Sestamibi | 34 | 36% | 100% | 79% | 100% | 77% |
| Oxidronate | 23 | 37% | 100% | 78% | 100% | 75% |
Mackie A, McCauley E, Cook AIM, Cadigan P, Bradford IMJ. A Comparison of the Accuracy of Reporting Axillary Lymph Node Involvement Using 99mTc.Sestamibi and 99mTc.Oxidronate Scintimammography in Breast Cancer Patients Poster presentation at the British Nuclear Medicine Society AGM, Brighton, April 2000, Nuc Med Commun 2000; 21 (4): 401P.
Dr. Alison Mackie, Durham Unit, Durham. Tel: +44 (0)191-333-2219.
Regional Medical Physics Department, Newcastle General Hospital, Newcastle upon Tyne, NE4 6BE, UK.
Tel: +44 (0)191-233-6161 Fax: +44 (0)191-226-0970 E-mail: webmaster@rmpd.org.uk Web: http://www.rmpd.org.uk
By using this site you agree to our Terms and Conditions of Use. Please read our legal page.
Regional Medical Physics Department, a Clinical Directorate of the Newcastle upon Tyne Hospitals NHS Foundation Trust.
Copyright ©1999-2008 All Rights Reserved. Revised 28 April, 2008.
